Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: A systematic review and meta-analysis

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4526-4537

  Eng, Lawson ^a,b   Azad, Abul Kalam ^a   Habbous, Steven ^a   Pang, Vincent ^a   Xu, Wei ^a,b   Maitland van Der Zee, Anke H ^d   Savas, Sevtap ^c   Mackay, Helen J ^b   Amir, Eitan ^b   Liu, Geoffrey ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DANUSERTIB; ENDOSTATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NEUROPILIN 1; PACLITAXEL; PEMETREXED; SORAFENIB; TAXANE DERIVATIVE; TELATINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; BLEEDING; CANCER CELL; CANCER RECURRENCE; CANCER SURVIVAL; CHEILITIS; CHRONIC GRANULOCYTIC LEUKEMIA; DRUG EFFICACY; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAND FOOT SYNDROME; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERTENSION; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; NEOPLASM; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN POLYMORPHISM; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; SYSTEMATIC REVIEW; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS, PHARMACOLOGICAL; DISEASE-FREE SURVIVAL; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROGNOSIS; TRANSLATIONAL MEDICAL RESEARCH; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865761089     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1315     Document Type: Review

References (74)

1. McDougall SR, Anderson AR, ChaplainMA. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol 2006;241:564-89.
2. Ulahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 2011;29:325-37.
3. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009;8:2496-508.
4. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med 2011;5:795-806.
5. dbSNP home page [homepage on the Internet]. Bethesda, MD: National Center for Biotechnology Information; 2012. [Updated 2012 Mar 19; cited June 05, 2012]. Available from: http://www.ncbi.nlm.nih.gov/projects/SNP/index.html.
6. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157-62.
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
8. Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In:Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester, UK: John Wiley & Sons, Ltd; 2006. p. 243-93.
9. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8.
10. Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X, et al. Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 2011;71:921-8.
11. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, et al. Retrospective exploratory analysis of VEGF polymorphismsin the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 2011;11:247.
12. Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 2011;26:143-51.
13. Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, et al. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res 2010;30:4209-17.
14. Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011;29:1140-5.
15. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008;14:7554-63.
16. Smerdel MP, Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010;118:167-71.
17. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010;29:95.
18. Sakaeda T, Yamamori M, Kuwahara A, Hiroe S, Nakamura T, Okumura K, et al. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in japanese patients. Ther Drug Monit 2008;30:497-503.
19. Steeghs N, Mathijssen RH, Wessels JA, de Graan AJ, van der Straaten T, Mariani M, et al. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Invest New Drugs 2011;29:953-62.
20. Steeghs N, Gelderblom H, Wessels J, Eskens FA, de Bont N, Nortier JW, et al. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patientswith solid tumors. Invest New Drugs 2011;29:137-43.
21. Balasubramanian SP, Cox A, Cross SS, Higham SE, Brown NJ, Reed MW. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer 2007;121:1009-16.
22. Kidd LR, Brock GN, VanCleave TT, Benford ML, Lavender NA, Kruer TL, et al. Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival. Cancer Causes Control 2010;21:1545-57.
23. Knechtel G, Hofmann G, Gerger A, Renner W, Langsenlehner T, Szkandera J, et al. Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer. J Cancer Res Clin Oncol 2010;136:1813-9.
24. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005;65:5015-9.
25. Forsti A, Jin Q, Altieri A, Johansson R, Wagner K, Enquist K, et al. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Res Treat 2007;101:83-93.
26. Balasubramanian SP, Cross SS, Globe J, Cox A, Brown NJ, Reed MW. Endostatin gene variation and protein levels in breast cancer susceptibility and severity. BMC Cancer 2007;7:107.
27. Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 2009;48:563-9.
28. Vidaurreta M, Sanchez-Munoz R, Veganzones S, Rafael S, Gutierrez M, de-la-Orden V, et al. Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer. Rev Esp Enferm Dig 2010;102:20-31.
29. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008;19:1734-41.
30. Hansen TF, Garm Spindler KL, Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A. The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenomics J 2011;11:53-60.
31. Zhang W, Gordon M, Press OA, Rhodes K, Vallbohmer D, Yang DY, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet Genomics 2006;16:475-83.
32. Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008;14:62-6.
33. Hansen TF, Sorensen FB, Spindler KL, Olsen DA, Andersen RF, Lindebjerg J, et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch 2010;456:251-60.
34. Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, Kulke MJ, et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009;15:4680-5.
35. Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Ayazi S, et al. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg 2010;251:857-64.
36. Lorenzen S, Panzram B, Keller G, Lordick F, Herrmann K, Becker K, et al. Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction. Mol Imaging Biol 2011;13:178-86.
37. Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, et al. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer 2009;45:3326-35.
38. Guan X, Zhao H, Niu J, Tan D, Ajani JA, Wei Q. Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer. J Exp Clin Cancer Res 2009;28:94.
39. Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol 2010;21:78-86.
40. Tzanakis N, Gazouli M, Rallis G, Giannopoulos G, Papaconstantinou I, Theodoropoulos G, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 2006;94:624-30.
41. Al-Moundhri MS, Al-Nabhani M, Burney IA, Al-Farsi AA, Al-Bahrani B. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms-a case-control study in an omani population. Mol Carcinog 2009;48:1170-6.
42. Kim JG, Sohn SK, Chae YS, Cho YY, Bae HI, Yan G, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 2007;18:1030-6.
43. Kawai Y, Sakano S, Korenaga Y, Eguchi S, Naito K. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 2007;52:1147-55.
44. Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005;65:70-5.
45. Mucci LA, Stark JR, Figg WD, Schumacher F, Li H, Abe M, et al. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: a prospective study. Int J Cancer 2009;125:1143-6.
46. Li HC, Cai QY, Shinohara ET, Cai H, Cao C, Wang ZF, et al. Endostatin polymorphism 4349G/A(D104N) is not associated with aggressiveness of disease in prostate [corrected] cancer. Dis Markers 2005;21:37-41.
47. Hefler LA, Mustea A, Konsgen D, Concin N, Tanner B, Strick R, et al. Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 2007;13:898-901.
48. Polterauer S, Grimm C, Mustea A, Concin N, Tanner B, Thiel F, et al. Vascular endothelial growth factor gene polymorphisms in ovarian cancer. Gynecol Oncol 2007;105:385-9.
49. Lose F, Nagle CM, O'Mara T, Batra J, Bolton KL, Song H, et al. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol Oncol 2010;119:479-83.
50. Smerdel MP, Waldstrom M, Brandslund I, Steffensen KD, Andersen RF, Jakobsen A. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer 2009;19:578-84.
51. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010;117:109-16.
52. Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, et al. Inherited determinants of ovarian cancer survival. Clin Cancer Res 2010;16:995-1007.
53. Amano M, Yoshida S, Kennedy S, Takemura N, Deguchi M, Ohara N, et al. Association study of vascular endothelial growth factor gene polymorphisms in endometrial carcinomas in a japanese population. Eur J Gynaecol Oncol 2008;29:333-7.
54. Kim YH, Kim MA, Park IA, Park WY, Kim JW, Kim SC, et al. VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival. Gynecol Oncol 2010;119:232-6.
55. Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856-62.
56. Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang LE, et al. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 2010;10:431.
57. Dong J, Dai J, Shu Y, Pan S, Xu L, Chen W, et al. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a chinese population. Carcinogenesis 2010;31:1080-6.
58. Masago K, Fujita S, Kim YH, Hatachi Y, Fukuhara A, Nagai H, et al. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci 2009;100:1917-22.
59. Kong SY, Park JW, Lee JA, Park JE, Park KW, Hong EK, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 2007;46:446-55.
60. Wu LM, Xie HY, Zhou L, Yang Z, Zhang F, Zheng SS. A single nucleotide polymorphism in the vascular endothelial growth factor gene is associated with recurrence of hepatocellular carcinoma after transplantation. Arch Med Res 2009;40:565-70.
61. Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006;94:1879-86.
62. Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 2006;107:4871-9.
63. Kim DH, Lee NY, Lee MH, Sohn SK, Do YR, Park JY. Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. Br J Haematol 2008;140:71-9.
64. Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S, et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol 2010;21:1179-88.
65. Kim DH, Kong JH, Byeun JY, Jung CW, Xu W, Liu X, et al. The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2010;16:5339-50.
66. Diao LP, Yu XM, Gao YH, Li Y, Liu HS, Liu LH, et al. Association of VEGF genetic polymorphisms with the clinical characteristics of non-hodgkin's lymphoma. J Cancer Res Clin Oncol 2009;135:1473-81.
67. Ruiz MT, Biselli PM, Maniglia JV, Pavarino-Bertelli EC, Goloni-Bertollo EM. Genetic variability of vascular endothelial growth factor and prognosis of head and neck cancer in a brazilian population. Braz J Med Biol Res 2010;43:127-33.
68. Formento JL, Etienne-Grimaldi MC, Francoual M, Pages G, Onesto C, Formento P, et al. Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer. Pharmacogenomics 2009;10:1277-83.
69. International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299-320.
70. Ocana A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011;29:254-6.
71. Zhai R, Liu G, Zhou W, Su L, Heist RS, Lynch TJ, et al. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res 2008;14:612-7.
72. Hussein A, Askar E, Elsaeid M, Schaefer F. Functional polymorphisms in transforming growth factor-beta-1 (TGFbeta-1) and vascular endothelial growth factor (VEGF) genes modify risk of renal parenchymal scarring following childhood urinary tract infection. Nephrol Dial Transplant 2010;25:779-85.
73. Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004;122:209-15.
74. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000;12:1232-5.